Transformational Acquisition of Ayumi Pharmaceutical Holdings
Filed with TSE · · 28 pages · English
1. Transaction Highlights 2. Transaction Overview and Compelling Rationale 3. Ayumi Pharmaceutical Holdings Overview 4. GNI Group Overview 1. Transaction Highlights Transaction Highlights GNI Group to acquire 100% ownership of Ayumi Pharmaceutical Holdings from a Blackstone-led shareholder group for JPY 44.8 billion in equity consideration, with closing expected shortly. Ayumi’s CALONAL tablets ho
Earlier from GNI
- Financial Results Briefing for Q2 FY 2025 (on August 29, 2025)
- FY2023Q1 Earnings Call Transcript
- Amendment of “Q1 FY2023 Financial Results Corporate Presentation” document
- Q1 FY2023 Financial Results Corporate Presentation
- GNI Group: CBIO files 2023Q1 10-Q (quarterly report)
Later from GNI
- GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
- Notice Concerning Filing of Form S-3 Registration Statement by Gyre Therapeutics
- Notice Regarding the Execution of a Loan Agreement Containing Financial Covenants
- Notice Concerning the Completion of the Acquisition of All Shares of AYUMI Pharmaceutical Holdings KK (Conversion into a Wholly-Owned Subsidiary)
- Consolidated Financial Results for Q2 FY2026 (IFRS)
Follow GNI into a list and get an email when it puts out news.
Follow GNI